CliffBio
small molecule

GLYRX-PF

GLYCOPYRROLATE

Loss of exclusivity—loss of exclusivity
CompanyExela Pharma Sciences Llc →See this company's full patent-cliff portfolio

Drug detail

Brand nameGLYRX-PF
Active ingredientGLYCOPYRROLATE
Strength0.6MG/3ML (0.2MG/ML)
Dosage formSOLUTION
RouteINTRAMUSCULAR, INTRAVENOUS
ModalitySmall molecule
FDA approvalDecember 2020
Marketing statusDISCN

More from Exela Pharma Sciences Llc

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.